Abstract

Engineered cardiac tissues fabricated from human induced pluripotent stem cells (hiPSCs) show promise for ameliorating damage from myocardial infarction, while also restoring function to the damaged left ventricular (LV) myocardium. For these constructs to reach their clinical potential, they need to be of a clinically relevant volume and thickness, and capable of generating synchronous and forceful contraction to assist the pumping action of the recipient heart. Design prerequisites include a structure thickness sufficient to produce a beneficial contractile force, prevascularization to overcome diffusion limitations and sufficient structural development to allow for maximal cell communication. Previous attempts to meet these prerequisites have been hindered by lack of oxygen and nutrient transport due to diffusion limits (100–200 μm) resulting in necrosis. This study employs a layer-by-layer (LbL) fabrication method to produce cardiac tissue constructs that meet these design prerequisites and mimic normal myocardium in form and function. Thick (>2 mm) cardiac tissues created from hiPSC-derived cardiomyocytes, -endothelial cells (ECs) and -fibroblasts (FBs) were assessed, in vitro, over a 4-week period for viability (<6% necrotic cells), cell morphology and functionality. Functional performance assessment showed enhanced t-tubule network development, gap junction communication as well as previously unseen, physiologically relevant conduction velocities (CVs) (>30 cm/s). These results demonstrate that LbL fabrication can be utilized successfully to create prevascularized, functional cardiac tissue constructs from hiPSCs for potential therapeutic applications.

Highlights

  • The use of engineered cardiac muscle patch constructs focusing on repair and functional restoration following an acute myocardial infarction (AMI), have shown promise in improving clinical outcomes for patients (Lake et al, 1985; Lucas and Szweda, 1999; Murphy and Steenbergen, 2008)

  • Thick Layer-By-Layer Human Cardiac Patch search continues for an effective method of restoring both mechanical and electrical function to the AMI damaged region of the heart, which is necessary for a successful therapeutic application

  • We demonstrated that our LbL fabrication method yields thick, vascularized engineered cardiac tissue, with conduction velocities (CVs) ranging between 17 and 19 cm/s, as well as viscoelastic properties that were similar to native murine myocardial tissue (Pretorius et al, 2020), yet this study only utilized CMs and endothelial cells (ECs)

Read more

Summary

Introduction

The use of engineered cardiac muscle patch constructs focusing on repair and functional restoration following an acute myocardial infarction (AMI), have shown promise in improving clinical outcomes for patients (Lake et al, 1985; Lucas and Szweda, 1999; Murphy and Steenbergen, 2008). Cell therapy approaches utilizing products associated with human induced pluripotent stem cells (hiPSCs) have been examined pre-clinically as a viable therapeutic option (Xiaojun et al, 2012, 2014; Ye et al, 2014). Electrical function is largely dependent upon the electrical excitability of the cells and subsequently the engineered tissue Due to their immature phenotype, hiPSC-derived cardiomyocytes (iCMs) tend to have reduced electrical excitability compared to mature, adult CMs found in the native myocardium (O’Hara et al, 2011; Mummery et al, 2012)

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call